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Objective High level of both Angiotensin (Ang) II and Tumor Necrosis Factor (TNF)-α heve been 
implicated in the pathogenesis of glomerular injury by affecting podocytes. The aim of this study 
was to investigate the Ang II-TNF-α relationship in human podocytes. 
Methods Immortalized podocytes were exposed to Ang II for 6 days in the absence or presence of 
either losartan or PD123,319 (both at 100 nM), AT1 and AT2 receptor antagonists, respectively. 
Results Ang II, after at least 72 h of repeated treatment, increased basal TNFA expression and 
cytokine release with a biphasic pattern and the maximum response at 10 nM. Losartan dampened 
the Ang II effects on TNF-α production throughout all the experimental period, demonstrating an 
AT1 contribution. PD123,319 affected the second TNF-α production peak showing even an AT2 
receptor contribution. Moreover, Ang II causes TNFR1 and TNFR2 over-expression in a time-
dependent manner. The functional interaction between Ang II and TNF-α has been demonstrated 
when the pro-proliferative effect of Ang II was antagonized by a neutralizing TNF-α antibody. 
Conclusions In conclusion, our results point out a functional interaction between Ang II and TNF-α 
and indicate this cytokine as a mediator in Ang II long-term pathoadaptive podocytes changes.  
 
 




Clinical studies have shown that the angiotensin-converting-enzyme inhibitors (ACEi) and the 
angiotensin II-receptor blockers (ARB) exert significantly nephroprotective effects by decreasing 
proteinuria and disease progression both in patients affected by diabetic and non diabetic 
nephropathies [1, 2]. These data suggest a relevant contribution of the angiotensin (Ang) II signal to 
the development of glomerular dysfunction. Podocytes are terminally differentiated epithelial cells 
[3] and constituents of the glomerular filtration barrier (GFB). Their dysfunction and loss have been 
implicated in the onset and progression of glomerular diseases. These cells express all the 
components of the renin-angiotensin system (RAS) and are a major source of intraglomerular Ang 
II [4]. Ang II production results in being enhanced in podocytes following their exposure to 
mechanical stretch and hyperglycemia [5, 6]. Moreover, the expression of both AT1 and AT2 Ang II 
receptors on podocyte plasma membrane suggests that could be targeted by Ang II [7]. It has been 
demonstrated in podocytes that Ang II promotes actin rearrangement, tight junction protein ZO-1 
and nephrin protein down-regulation, thus leading to proteinuria, as well as an increase of vascular 
endothelial growth factor (VEGF) and transforming growth factor (TGF)-synthesis and, finally, it 
triggers apoptosis [8, 9]. Since podocyte response to Ang II may be a complex mixture of both 
direct and indirect effects, a further elucidation is warranted, particularly by testing the effects of a 
prolonged cell exposure to the vasopeptide with the aim of mimicking the clinical condition of a 
chronic exposure to high level of Ang II.  
The proinflammatory cytokine tumor necrosis factor (TNF)-α has been reported to participate in the 
pathogenesis of glomerular injury. In particular, high levels of TNF-α mRNA were found in the 
glomeruli of rodents and patients with diabetic nephropathy [10, 11], and this overexpression has 
been associated with the development of renal injury, leading to microalbuminuria [12, 13]. TNF-α 
is expressed and released not only by infiltrating leukocytes but also by resident cells, including 
endothelial, mesangial and tubular epithelial cells [14]. Among the many deleterious effects, TNF-α 
in the kidney promotes an inflammatory response and the accumulation of extracellular matrix thus 
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reducing the glomerular blood flow and damaging the GFB [15]. Recently, Bruggeman et al. (2011) 
have demonstrated that TNF-α, through the TNFR2-NF-κB pathway, contributes to the 
proliferative and pro-inflammatory phenotype of diseased podocytes [16]. The detrimental role of 
TNF-α in the pathogenesis of glomerular injury has been confirmed by the attempt to use TNF-α 
antagonists to treat glomerular diseases [17]. Infliximab, a chimeric monoclonal antibody against 
TNF-α, has been reported to significantly decrease albuminuria in a rat model of diabetic 
nephropathy [18].  
In vitro studies suggest that a functional linkage between Ang II and TNF-α may exist, having been 
demonstrated that Ang II induces TNF-α expression in endothelial and mesangial cells [19, 20]. 
However, at the best of our knowledge, whether Ang II could promote TNF-α production by 
podocytes remains still an unsolved question. As the high level of both Ang II and TNF-α have 
been reported in chronic progressive glomerular diseases, where podocytes dysfunction plays a 
critical role (i.e., hypertensive nephropathy, diabetic nephropathy, classic focal segmental 
glomerulosclerosis) [15, 21-23], the aim of this study was to investigate the Ang II-TNF-α 






MATERIALS AND METHODS 
Drugs and chemicals 
Ang II, TNF-α, losartan, PD123,329 and all other reagents were from Sigma-Aldrich (Milan, Italy). 
Ang II receptor antagonists were dissolved in dimethylsulfoxide, TNF-α in water, as indicated by 
manufacturers’ instructions. Final drug concentrations were obtained by dilution of stock solutions 
in the experimental buffers. The final concentration of organic solvent was less than 0.1%, which 
has no effect on cell viability. In all experiments un-stimulated cells served as controls. 
 
Cell cultures 
Primary cultures of human podocytes were kindly provided by Prof. G. Camussi (Department of 
Internal Medicine and Center for Molecular Biotechnology, University of Turin, Turin, Italy). 
Podocytes were characterized and cultured as previously reported [24, 25]. 
 
Citokine release 
TNF-α release was evaluated by measuring cytokine concentration in the experimental medium by 
the Instant ELISA system (Bender MedSystems, GmbH, W., Austria) following the manufacturers’ 
instructions. All experiments were performed with 30 × 103 cells/well as initial cell density and 
results were corrected for the number of cells (cell growth) and are expressed as percent change 
over the control. 
 
RT-PCR and quantitative real-time PCR analysis 
The analyses were performed as previously described [25, 26]. Briefly, RT-PCR amplifications 
were performed in 25 µl reaction mixtures containing 1.0 µl of cDNA, 2.5 µl of 10× buffer, 1.0 µl 
of 50 mM MgCl2, 0.20 µl of 25 mM dNTPs mix, 0.05 U of EuroTaq DNA polymerase (Euroclone, 
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Milan, Italy), and 2.5 nM of each primer. PCR amplicons were resolved in an ethidium bromide-
stained agarose gel (2%-3%) by electrophoresis, and signals were quantified using NIH Image J 
1.41 software. β-actin expression was used as an internal control (Table 1). Real-time PCR 
experiments were performed in 25 µl reaction mixtures containing 10 ng of cDNA template, the 
Power SYBR® Green PCR Master Mix and the AmpliTaq Gold® DNA Polymerase LD (Applied 
Biosystems). Relative quantization of the products was performed using a 48-well StepOne™ Real 
Time System (Applied Biosystems). For all real-time PCR analyses, β-actin mRNA was used to 
normalize RNA inputs (Table 1).  
 
Western blot analysis 
Cell culture dishes were washed with phosphate-buffered saline (PBS) before adding ice-cold lysis 
buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium 
deoxycholate, 5 mM EDTA, 1 µl/ml protease inhibitors, 0.1 mM ZnCl2, and 1 mM Ph-Me-Sul-Flu). 
Cell lysates were processed to determine protein concentrations using a BCA protein assay (Pierce 
Biotechnology Inc. Rockford, IL, USA) following the manufacturers’ instruction. Samples 
containing 20 µg of protein were subjected to SDS-PAGE using a 10% gel. Proteins were 
transferred to a PVDF membrane (Millipore, Bradford, USA), which was incubated with Super 
Block blocking buffer (Pierce Biotechnology Inc.). AT1R, TNFR1 and TNFR2 were detected 
following incubation with mouse monoclonal antibodies (Santa Cruz Biotechnology, CA, USA). 
ATR2 was detected following incubation with rabbit polyclonal antibody (Santa Cruz 
Biotechnology), according to the manufacturer’s instructions. To confirm the homogeneity of the 
proteins loaded, the membranes were stripped and incubated with an anti-β-actin monoclonal 
antibody (Sigma-Aldrich). The membranes were overlaid with Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer Life Science, Norwalk, CT, USA) and then 




Cell proliferation assay 
Podocytes (3000 cells/well) were exposed to Ang II 10 nM for 6 days according to an everyday 
medium changing protocol. In some experiments, at the day 3, a polyclonal goat anti-human IgG 
blocking TNF-α or a nonspecific polyclonal goat IgG (Santa Cruz Biotechnology) were added. The 
proliferative response was determined by counting the viable cells in a hemacytometer by the trypan 
blue exclusion test, blind by an observer.  
  
Data analysis 
Results are expressed as means ± SEM of at least three experiments. One-way analysis of variance 
(ANOVA) followed by the post hoc Dunnet's multiple comparison and Student –Newman-Keuls 
tests were used to determine significant differences between means. Differences were considered 





Effects of Ang II on TNF-α  production by human podocytes 
Our cell line posses both AT1 and AT2 receptors, as measured at both mRNA and protein level 
(Figure 1A and 1B). Their activation by Ang II stimulates TNF-α production as shown in Figure 2A 
and 2B. Cells were treated with Ang II (10 nM, 1-6 days) according to a daily exposure protocol 
and both TNFA expression and TNF-α release were measured (see materials and methods). The 
cytokine release showed a biphasic pattern with a first peak at the forth day and a second one at the 
sixth: medium TNF-α concentration was 14.9±3.0 pg/ml at day 0, 37.9±3.7 pg/ml at the forth day 
(about +150%; P<0.01) and 49.2±5.2 pg/ml at the sixth day (about +230%; P<0.01 vs both day 0 
and forth day). The same pattern was displayed by TNFA but with a ~24 h time-lag (Figure 2A).  
Ang II concentration-dependent curve (0.03-100 nM) disclosed a sigmoid shape with the maximum 
effect achieved from 10 nM and the EC50 at 0.43±0.02 nM (Figure 2B). These results demonstrate 
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that Ang II modulates TNF-α release by human podocytes in a time- and concentration-dependent 
manner. These effects are regulated at the gene level.  
 
Effects of losartan and PD123,319 on cytokine production induced by Ang II 
To evaluate whether AT1 and AT2 receptors contribute differently to Ang II response, podocytes 
were treated with the vasopeptide (10 nM, 1-6 days) in the presence or absence of selective AT1 or 
AT2 receptor antagonists, losartan (AT1) or PD123,319 (AT2), both at 100 nM (Figure 3). Only 
losartan was able to abolish Ang II effect on TNF-α release throughout all the experimental 
period. On the contrary, PD123,319 did not affect the first peak, but antagonized the second one 
(Figure 3). From these data it appears that Ang II response is differently and selectively mediated 
by both Ang II receptors. The same results were recorded by testing gene expression (data not 
shown). 
 
Effects of Ang II on TNF-α  receptor expression 
A further link between Ang II and TNF-α in human podocytes was discovered when the 
vasopeptide effect on TNF-α receptor expression was investigated at both mRNA and protein level. 
As previously, cells were exposed to 10 nM Ang II up to 6 days (Figure 4A and 4B). Ang II 
upregulated TNF-α receptors expression in a time-dependent manner starting respectively from the 
first day for TNFR2 and the third one for TNFR1.  
 
Effects of Ang II on human podocytes proliferation 
To evaluate whether the stimulatory agonism of Ang II on TNF-α production by human podocytes 
may have functional effects, the proliferative podocyte response to Ang II was tested. In 
comparison to medium alone, Ang II daily exposure increased cell growth rate: the cell number was 
significantly from the fourth day (Figure 5A). This effect was blunted by an αTNF-α neutralizing 
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antibody (at the third day; Figure 5B), thus suggesting that the Ang II induced proliferative response 




In this study we reported, in a concentration- and time-dependent manner, that Ang II inducesTNF-
α production by human podocytes. These results suggest that Ang II could activate a 
paracrine/autocrine loop centred on TNF-α. A similar positive effect of Ang II has been described 
in other kidney cells, such as cells from isolated tubules of rat medullary thick ascending limb and 
mesangial cells [19, 20], extending the evidence to the human podocytes. In our experiments Ang 
II, after at least 72 h of repeated treatment, increased basal TNFA expression and cytokine release 
with a biphasic pattern. Ang II-induced TNF-α release required a repeated exposure to the 
vasopeptide and it is related to the gene transcription. The analysis of the two kinetic profiles 
highlights a ~24 h-delay of release in comparison to gene expression, likely due to the multi-step 
process leading to mature TNF-α secretion [27]. Ang II up-regulates TNF-α in a concentration-
dependent manner (EC50s 0.43±0.02 nM) with the maximum response at 10 nM. Notably, these 
concentrations are within the intrarenal range reported to be ~one thousand times higher than the 
circulating one [28, 29]. Furthermore, our protocol, consisting of repeated stimulations, intended to 
mimic a chronic in vivo podocyte exposure to the vasopeptide. The everyday replacement of the 
medium with or without Ang II was planned to overcome Ang II catabolism [30]. Velez et al. 
(2007) have demonstrated that podocytes not only synthesize and release Ang II, but also convert it 
into the bioactive Ang (1-7) and Ang III [31]. The formation of these active metabolites has to be 
considered while discussing the data. However, as losartan, a selective AT1 antagonist, abolished 
the Ang II effects, the contribution of Ang (1-7), acting on the mas receptor [32], can be excluded. 
Even Ang III contribution can be rejected, because, even if it activates AT1 and AT2 receptors with 
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an affinity quite close to Ang II [32], its half life is ~5 fold shorter than the one of the parent peptide 
[31]. Thus, we may conclude that the observed effects are mainly due to Ang II. Taken these data 
together, our experimental conditions might be relevant to elucidate at least one of the podocytes 
pathoadaptive changes, TNF-α up-regulation, caused by a prolonged exposure to high concentration 
of Ang II, in the same way as it happens in chronic progressive glomerular disease where podocyte 
dysfunction plays a critical role (i.e., hypertensive nephropathy, diabetic nepfropathy, classic focal 
segmental glomerulosclerosis) [15, 21-23]. 
Previous findings indicate that in rat renal cortex [22, 33] and in human renal proximal tubular 
epithelial cells [34] the interaction between Ang II and TNF-α is mediated by AT1 receptors. These 
evidences have been confirmed by using a selective AT1 antagonist, such as losartan. Drug 
treatment dampened all the Ang II effects on TNF-α gene expression and release, throughout the 
entire experimental period. However, our results show that even AT2 receptors contribute to evoke 
the effects measured in the last period of the experimental observation, thus indicating a delayed 
involvement of theirs. This suggests that while the first peak reflects the AT1 receptor contribution 
on cytokine production, the second one seems to be driven by a more complex signaling.  
Another original result of this study is that Ang II, besides evoking TNF-α production, causes 
TNFR1 and TNFR2 over-expression, which might underlie an increased cell responsiveness to the 
cytokine. Actually, a functional interaction between Ang II and TNF-α has been demonstrated in 
our study when the pro-proliferative effect of Ang II was antagonized by a neutralizing TNF-α 
antibody. This experiment has been planned only to ascertain the cytokine role, being not able to 
elucidate the relative contribution of the two TNF-α receptor types. However, the kinetic data 
depicted in figure 4 indicate a more rapid and more intense modulation by Ang II of the TNFR2 
expression in comparison to that of TNFR1. Interestingly, while TNFR1 has been implicated in cell 
death processes [14, 27], recent data indicate the TNF-α-TNFR2 axis as a candidate pathway 
contributing to the development of a proliferative and pro-inflammatory podocyte phenotype, 
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associated with proliferative podocytopathies [16]. Ore data are derived from cultured immortalized 
human podocytes that are proliferating cells. Therefore these observations are not in keeping with 
that podocytes are postmitotic terminally differentiated cells with little or no capacity for 
regenerative replication [35]. However, proliferating podocytes have been observed in experimental 
models of glomerular injury [36], which may be explained admitting that some podocytes reengage 
the cell cycle as an adaptive response to injury in an attempt to mitigate their loss [37]. Further, 
indirect evidence for podocyte proliferation in human diabetes stems from the increased numbers of 
podocytes that are detected in the urine long before any reduction in glomerular podocyte numbers 
[38, 39]. In our study, we have demonstrated that our model leads to an Ang II induced proliferation 
of human podocytes. A critical aspect of our model is the use of immortalized podocytes, that are a 
cell type which is able to proliferate by itself. While recognizing this experimental bias, we have to 
stress that an increase in proliferation rate was observed in the presence of Ang II, as well as its 
reduction after αTNF-α. Our results, consistently with previous data indicate that TNF-α could act 
as a mitogenic stimulus on podocytes [16] and suggest that the TNF-α release and the TNFRs 
expression, could mediate the proliferative effects induced by Ang II on podocytes.  
In conclusion, our results point out a functional interaction between Ang II and TNF-α and indicate 
this cytokine as a mediator in Ang II long-term pathoadaptive podocytes changes. These results get 
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TITTLES AND LEGENDS 
Figure 1. Basal AT1 and AT2 receptor expression by human podocytes. Representative pictures of 
AGTR1 and AGTR2 mRNAs detected by RT-PCR (A) or AT1 and AT2 proteins by Western blot 
analysis (B).  
 
Figure 2. Effects of Ang II on TNF-α production by human podocytes. (A) Podocytes were 
exposed to Ang II. Experimental medium and Ang II were replaced every day. Cells were processed 
for quantitative real-time PCR analysis and cytokine concentration in the supernatants were 
measured by ELISA. Data are expressed as percent change over the control (untreated cells; day 0). 
(B) Podocytes were exposed to increasing Ang II concentrations (0.03 – 100 nM) for 4 days and 
TNF-α release was measured by ELISA. Data are expressed as percentage of the maximal effect. 
Data are the mean ± SEM of three independent experiments performed in duplicate. *P<0.01 vs. 
control and #P<0.01 vs. first peak. 
 
Figure 3. Effects of losartan and PD123,319 on TNF-α production induced by Ang II. Podocytes 
were exposed to Ang II (10 nM, 1-6 days) in presence of losartan (100 nM) or PD123,319 (100 
nM). Experimental medium, Ang II and antagonists were replaced every day. Cytokine 
concentration in the supernatants was measured by ELISA. Results are expressed as percent change 
over the control (untreated cells; day 0). Data are the mean ± SEM of three independent 
experiments performed in duplicate. *P<0.01 vs. control. 
 
Figure 4. Effects of Ang II on TNFR1 and TNFR2 receptor expression. Podocytes were exposed to 
Ang II. Experimental medium and Ang II were replaced every day and cells were processed for 
quantitative real-time PCR analysis (A) or Western blot analysis, pictures shown are representative 
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of three independent experiments (B). Results are expressed as percent change over the control 
(untreated cells; day 0). Data are the mean ± SEM of three independent experiments performed in 
duplicate. *P<0.01 vs. control. 
 
Figure 5. Effects of Ang II on proliferative response of human podocyte. (A) Cells were cultured in 
the absence or presence of Ang II (10 nM, 1-6 days) Experimental medium and Ang II were 
replaced every day. (B) Cells were cultured for 4 days, on the day 3 αTNF-α or nonspecific 
polyclonal goat IgG were added. Results are expressed as cells/well. Data are the mean ± SEM of 
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344 95°C, 60 s 62°C, 60 s 72°C, 60 s 35 
Tnfr1 F:5’-TCTATGCCCGAGTCTCAACC-3’ 
R:5’-GGTGAGGGACCAGTCCAATA-3’ 
244 94°C, 30 s 55°C, 30 s 72°C, 120 s 35 
Tnfr2 F:5’-AACTGGGTTCCCGAGTGCTTG-3’ 
R:5’-AGTGCTGGGTTCTGGAGTTGG-3’ 
629 94°C, 30 s 64°C, 30 s 72°C, 120 s 35 
AGTR1 F:5’-AGCCAAATCCCACTCAAACCT-3’ 
R:5’-TCGAACATGTCACTCAACCTCA-3’ 
120 94°C, 30 s 
 






302 94°C, 30 s 
 






660 95°C, 45 s 60°C, 45 s 72°C, 90 s 25 
	  
 
